Announcement of a grant of patent for innovative new high-throughput single-cell analysis technology in US 2022.03.29.

We are pleased to inform you that the patent we applied for the new drug candidate search technology has been granted in the United States.

This patent is regarding a technique for selecting cells that produce a target substance that specifically binds to a cell membrane protein more quickly and efficiently, and a technique relating to a novel single-cell analysis technology (Rapid isolation of GPCR-specific Antibody by Single-cell Screening System: RiGRASSTM) that produces target substances such as antibodies using cells selected by foregoing technology.

[US Patent Application Number] US 17 / 431,268

[Public number] WO2020 / 171020

[Assessment date] March 24, 4th year of Reiwa (2022.3.24)

[Title of the invention]

Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent

We are now able to evaluate antibodies that specifically bind to the G protein-coupled receptor (GPCR) targeted for drug discovery in a shorter period of time than more antibody-producing B cells. We will continue to promote the development of therapeutic agents for antibodies that bind to and act on GPCRs, which have been said to be difficult to obtain.